2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1491

Systemic Sclerosis – Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A On Effector Cells
Abstract Number: 722

Systemic Sclerosis Associated Pulmonary Hypertension – Is Pulmonary Veno-Occlusive Disease As Common As They Say?
Abstract Number: 853

Systemic Sclerosis Classification Criteria: Developing Methods for Multi-Criteria Decision Analysis
Abstract Number: 1523

Systemic Vasculitis and Pregnancy: a Multicenter Study On Maternal and Neonatal Outcome of 43 Prospectively Followed Pregnancies
Abstract Number: 2085

T Cell-Mediated Murine Antigen-Induced Arthritis Is Resistant to Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts and Osteocytes in Vivo
Abstract Number: 2319

T Follicular Helper Cell and Regulatory T Cell Frequencies Are Affected by B Cell Depletion in Patients with Granulomatosis with Polyangiitis
Abstract Number: 2334

T-Cell Cross Reactivity with Citrullinated Antigen and P. Gingivalis Membrane Antigen Following Infection with P. Gingavalis and/or Injection of Citrullinated Mouse Type II Collagen in DBA/1J Mice
Abstract Number: 2387

Takayasu’s Arteritis: Features and Management of 216 Patients in China
Abstract Number: 2623

Taking Charge of Systemic Sclerosis: A Pilot Study of an Internet Self-Management Program
Abstract Number: 1177

Talin Is Cleaved and Expressed As a Short Form in Patients with Rheumatoid Arthritis
Abstract Number: L7

Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial
Abstract Number: 2153

Target-Directed Development of a Proposed Biosimilar Rituximab (GP2013): Comparability of Antibody-Dependent Cellular Cytotoxicity Activity and Pre-Clinical Pharmacokinetics and Pharmacodynamics with Originator Rituximab
Abstract Number: 1611

Targeted Deep Re-Sequencing Implicates Rare and Low Frequency Coding Variants in IL23R, MEFV, TLR4, and NOD2 in Behçet’s Disease
Abstract Number: 1786

Targeting CD1c-Expressing mDCs to Inhibit Increased Thymus and Activation Regulated Chemokine Levels in RA
Abstract Number: 848

Targeting Glycosphingolipid Biosynthesis Normalises T Lymphocyte Function in Patients with Systemic Lupus Eyrthematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].